ONKOLOGIE www.onkologiecs.cz 78 MONOKLONÁLNÍ GAMAPATIE PŘEHLED PŘÍNOSU DARATUMUMABU PRO LÉČBU VŠECH MONOKLONÁLNÍCH GAMAPATIÍ, ALE I DALŠÍCH NEMOCÍ A VLASTNÍ ZKUŠENOSTI S LÉČBOU 74 PACIENTŮ DARATUMUMABEM, LENALIDOMIDEM A DEXAMETAZONEM ab-refractory multiple myeloma can overcome refractoriness to both agents. Blood. 2018;131(4):464-467. doi: 10.1182/ blood-2017-10-809293. 37. Fedele PL, Willis SN, Liao Y, et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018;132(20):2166-2178. doi: 10.1182/ blood-2018-05-850727. 38. D’Souza C, Prince HM, Neeson PJ. Understanding the Role of T-Cells in the Antimyeloma Effect of Immunomodulatory Drugs. Front Immunol. 2021;12:632399. doi: 10.3389/ fimmu.2021.632399. 39. Cho SF, Lin L, Xing L, et al. Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies. 2017;6(4):18. doi: 10.3390/antib6040018. 40. Viola D, Dona A, Caserta E, et al. Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. Leukemia. 2021;35(1):189-200. doi: 10.1038/ s41375-020-0810-4. 41. Abramson HN. Immunotherapy of Multiple Myeloma: Promise and Challenges. Immunotargets Ther. 2021;10:343371. doi: 10.2147/ITT.S306103. 42. Nooka AK, Kaufman JL, Hofmeister CC, e al. Daratumumab in multiple myeloma. Cancer. 2019;125(14):2364-2382. doi: 10.1002/cncr.32065. 43. Morandi F, Horenstein AL, Costa F, et al. CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma. Front Immunol. 2018;9:2722. doi: 10.3389/fimmu.2018.02722. 44. Pittari G, Vago L, Festuccia M, et al. Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. Front Immunol. 2017;8:1444. doi: 10.3389/fimmu.2017.01444. 45. Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56:915-924. 46. Sanchez L, Richter J, Cho HJ, et al. Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma. Ther Adv Hematol. 2021;12:2040620720987075. doi: 10.1177/2040620720987075. 47. San-Miguel J, Usmani SZ, Mateos MV, et al. Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO). Haematologica. 2021;106(6):17251732. doi: 10.3324/haematol.2019.243790. 48. Xu XS, Dimopoulos MA, Sonneveld P, et al. Pharmacokinetics and exposure-response analyses of daratumumab in combination therapy regimens for patients with multiple myeloma. Adv Ther. 2018;35:1859-72. 49. Lokhorst HM, Plesner T, Laubach JP, et al. TargetingCD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373:1207-1219. 50. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387:1551-1560. 51. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128:37-44. 52. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754-766. 53. Bhatnagar V, Gormley NJ, Luo L, et al. FDA approval summary: daratumumab for treatment of multiple myeloma after one prior therapy. Oncologist. 2017;22:1347-1353. 54. Spencer A, Lentzsch S, Weisel K, et al. Daratumumabplus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103(12):2079-2087. doi: 10.3324/haematol. 55. Mateos MV, Sonneveld P, Hungria V, et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR. Clin Lymphoma Myeloma Leuk. 2020;20(8):509-518. doi: 10.1016/j. clml.2019.09.623. 56. Janssen Biotech. Darzalex (daratumumab) [package insert]. U.S. food and drug administration. Accessed from: https://www.accessdata.fda.gov/drugsatfda_docs/ label/2020/761036s029lbl.pdf. Accessed at: November 12, 2020. 57. Bhatnagar V, Gormley NJ, Luo L, et al. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. Oncologist. 2017;22(11):1347-1353. doi: 10.1634/theoncologist.2017-0229. 58. Dimopoulos MA, Oriol A, Nahi H, et al. POLLUX Investigators. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016;375(14):1319-1331. doi: 10.1056/NEJMoa1607751. 59. Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020;34 (7):1875-1884. doi: 10.1038/s41375-020-0711-6. 60. Mateos MV, Spencer A, Pour L, et al. Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. Haematologica. 2020;105(2):468-477. doi: 10.3324/haematol.2019.217448. 61. Avet-Loiseau H, San-Miguel J, Casneuf T, et al. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39(10):1139-1149. doi: 10.1200/JCO.20.01814. 62. Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088-2096. doi: 10.3324/haematol.2018.194282. 63. Kaufman JL, Dimopoulos MA, White D, et al. Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX. Blood Cancer J. 2020;10(11):111. doi: 10.1038/s41408-020-00375-2. 64. Cavo M, San-Miguel J, Usmani SZ, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139(6):835-844. doi: 10.1182/blood. 65. Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/ or refractory multiple myeloma. Blood. 2017;130:974-981. 66. Vermeulen J, Carson R, Sonneveld P. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3trial. Lancet Oncol. 2021;22(6):801-812. doi: 10.1016/S1470-2045(21)00128-5. 67. Moreau P, Baldini L, Symeonidis A, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801812. doi: 10.1016/S1470-2045(21)00128-5. 68. Dimopoulos MA, Terpos E, Boccadoro M, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone inpreviously treated multiple myeloma (APOLLO): an openlabel, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801812. doi: 10.1016/S1470-2045(21)00128-5. 69. Qureshi A, Rhee JH. Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. BMJ Case Rep. 2021;14(3):e240168. doi 10.1136/bcr-2020-240168. 70. Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a ran- domised, multicentre, open-label, phase 3 study. Lancet (London, England). 2020;396:186-197. 71. LeLeu X, Beksac M, Pour L, et al. Efficacy and safety of weekly carfilzomib (70mg/m2), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. Leukemia & lymphoma. 2021;62(2):358-367. 72. Leleu X, Chari A, Richard S, et al. A combination of carfilzomib, dexamethasone, and daratumumab for treatment of adult patients with relapsed/refractory multiple myeloma in two dosing regimens: once-weekly and twiceweekly. Expert Rev Hematol. 2021;14(12):1049-1058. doi: 10.1080/17474086.2021.1955343. 73. Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised,multicentre, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65-76. doi:10.1016/S1470-2045(21)00579-9. 74. Quach H, Nooka A, Samoylova O, et al. Carfilzomib, dexamethasone and daratumumab in relapsed or refraktory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy. Br J Haematol. 2021;194(4):784-788. doi: 10.1111/bjh.17541. 75. Richard S, Jagannath S, Cho HJ, et al. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refraktory multiple myeloma. Expert Rev Hematol. 2021;14(1):31-45. doi: 10.1080/17474086.2021.1858790. 76. San-Miguel J, Avet-Loiseau H, Paiva B, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139(4):492-501. doi: 10.1182/ blood.2020010439. 77. Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3trial. Lancet. 2020;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. 78. Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Frailty Subgroup Analysis of ALCYONE. Clin Lymphoma Myeloma Leuk. 2021;21(11):785798. doi: 10.1016/j.clml.2021.06.005. 79. Cavo M, Dimopoulos MA, San-Miguel J, et al. Comparative Efficacy of Bortezomib, Melphalan, and Prednisone (VMP) With or Without Daratumumab Versus VMP Alone in the Treatment of Newly Diagnosed Multiple Myeloma: Propensity Score Matching of ALCYONE and VISTA Phase III Studies. Clin Lymphoma Myeloma Leuk. 2020;20(7):480-489. doi: 10.1016/j.clml.2020.02.018. 80. Parasrampuria DA, He J, Zhang L, et al. Comparison of efficacy from two different dosing regimens of bortezomib: an exposure-response analysis. Br J Haematol. 2020;189(5):860868. doi: 10.1111/bjh.16446. 81. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019;394:29-38. 82. Moreau P, Hulin C, Perrot A, et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(10):1378-1390. doi:10.1016/S1470-2045(21)00428-9. 83. Roussel M, Moreau P, Hebraud B, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality
RkJQdWJsaXNoZXIy NDA4Mjc=